Clinical bottom line
Uterine artery Doppler (UAD) screening in the second and third trimesters shows promise as a noninvasive tool to identify pregnancies at increased risk for adverse outcomes such as preeclampsia, fetal growth restriction (FGR), and hypertensive disorders. Recent studies reinforce its predictive value particularly in high-risk populations, though sensitivity and specificity vary by gestational age, maternal factors, and Doppler parameters used. While not yet a standalone diagnostic test, UAD can augment clinical risk stratification and guide closer surveillance or early intervention strategies. Clinicians should interpret UAD results in the context of comprehensive clinical assessment and evolving evidence.
What the evidence shows
Uterine artery Doppler measures, including the pulsatility index (PI) and presence of notching, reflect uteroplacental blood flow and vascular resistance, which correlate with placental insufficiency and adverse perinatal outcomes. Multiple recent cohort and prospective studies have evaluated its utility:
- Golgelioglu et al. (2026) demonstrated that the uterine artery PI’s predictive performance for composite adverse perinatal outcomes in late-onset FGR is influenced by maternal age, with better discrimination in younger women. This highlights the need to consider demographic factors when interpreting UAD results.
- Mukka Sravani et al. (2024) found that mid-trimester UAD in high-risk pregnancies predicted adverse outcomes including preeclampsia and FGR, supporting its role as a screening tool in this subgroup.
- Kusumlata et al. (2026) reported that second-trimester UAD parameters were significantly associated with adverse outcomes in hypertensive pregnancies, suggesting utility in early identification of patients who may benefit from intensified monitoring.
- Hiremath Shraddha S. et al. (2024) confirmed that UAD screening can help predict preeclampsia and FGR, though they emphasized variability in sensitivity and specificity across populations.
- Ashraf et al. (2013) in a multicenter study showed that UAD screening in the second and third trimesters could identify pregnancies at risk for adverse outcomes, but noted that combining UAD with other clinical and biochemical markers improved predictive accuracy.
- Elsayed Omar Khalil et al. (2026) prospectively confirmed the association between abnormal UAD findings and adverse pregnancy outcomes, reinforcing its potential as part of a multimodal screening approach.
Collectively, these studies suggest that UAD is a valuable adjunctive tool for risk stratification, especially in pregnancies complicated by hypertension or suspected placental dysfunction.
Caveats and uncertainty
Despite encouraging data, several limitations temper the clinical application of uterine artery Doppler screening:
- Variability in Doppler technique, timing of assessment, and cutoff values for abnormal PI or notching complicate standardization and comparison across studies.
- Predictive performance is moderate; false positives and negatives occur, limiting UAD’s utility as a sole screening test.
- Maternal factors such as age, parity, and comorbidities influence Doppler indices and must be accounted for to avoid misclassification.
- Most evidence derives from observational cohorts with heterogeneous populations; randomized controlled trials assessing UAD-guided management strategies remain sparse.
- Integration with other biomarkers (e.g., serum placental growth factor) and clinical risk models may enhance predictive accuracy but requires further validation.
- The impact of UAD screening on clinical outcomes, including whether earlier detection translates to improved maternal-fetal health, is not yet definitively established.
How this may change practice
Uterine artery Doppler screening is increasingly recognized as a useful component of antenatal risk assessment, particularly for women at elevated risk of hypertensive disorders and placental insufficiency. Incorporating UAD into routine evaluation in the second trimester could enable earlier identification of pregnancies warranting intensified surveillance or prophylactic interventions such as low-dose aspirin.
Clinicians should:
- Consider UAD screening in high-risk pregnancies, including those with chronic hypertension or prior adverse outcomes.
- Interpret Doppler findings alongside clinical context and other diagnostic modalities rather than in isolation.
- Stay informed on evolving guidelines and emerging evidence regarding optimal timing, parameters, and integration with biochemical markers.
- Advocate for standardized protocols to improve reproducibility and comparability of UAD assessments.
- Recognize the current limitations and avoid over-reliance on UAD results without corroborating clinical data.
Future research should focus on prospective trials evaluating whether UAD-guided management improves perinatal outcomes and on refining multimodal predictive algorithms.